Brexpiprazole Treatment for Bipolar I Depression

Recruiting Phase 3 Interventional Study
Bipolar Depression
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
58 (estimated)
Sponsor
Douglas Mental Health University Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Bipolar disorder (BD) is a frequent and lifelong recurrent mood disorder with treatment-resistant depressive episodes. Importantly, depressive symptoms and cognitive decline are major determinants of functionality and quality of life in this clinical population. There is robust evidence that individuals with BD have neurocognitive deficits (especially in memory and executive functioning domains) c…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Patient Inclusion Criteria: * Age: 18-75 * Male or female * Bipolar Disorder type I or type II * Current treatment-resistant depressive episode (with MADRS \>/= 24 and item 2 (reported sadness) \>/= 3) for a minimum of 2 weeks but \</= 52 weeks at screening visit and baseline visit * Patients must …
Contacts

Nada Khalil, BA

514 444 5397

nada.khalil.comtl@ssss.gouv.qc.ca

CONTACT

Paola Lavin Gonzalez, MD, MSc

438 389 8181

maria.lavingonzalez@mail.mcgill.ca

CONTACT